{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:05:59Z","timestamp":1791947159764,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":547,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.exphem.2022.09.003","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:34:20Z","timestamp":1664494460000},"page":"14-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Role of ASXL1 in hematopoiesis and myeloid diseases"],"prefix":"10.1016","volume":"115","author":[{"given":"Xin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6099-5324","authenticated-orcid":false,"given":"Nathalie","family":"Droin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren G.","family":"Banaszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Churpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-1341","authenticated-orcid":false,"given":"Eric","family":"Solary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2022.09.003_bib0001","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1242\/dev.125.7.1207","article-title":"The Additional sex combs gene of Drosophila encodes a chromatin protein that binds to shared and unique Polycomb group sites on polytene chromosomes","volume":"125","author":"Sinclair","year":"1998","journal-title":"Development"},{"key":"10.1016\/j.exphem.2022.09.003_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cell.2017.08.002","article-title":"Genome regulation by polycomb and trithorax: 70 years and counting","volume":"171","author":"Schuettengruber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2022.09.003_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ydbio.2009.10.004","article-title":"Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice","volume":"337","author":"Fisher","year":"2010","journal-title":"Dev Biol"},{"key":"10.1016\/j.exphem.2022.09.003_bib0004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gene.2005.10.033","article-title":"Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family","volume":"369","author":"Fisher","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.exphem.2022.09.003_bib0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-1119(03)00430-X","article-title":"A human homolog of Additional sex combs, additional sex combs-like 1, maps to chromosome 20q11","volume":"306","author":"Fisher","year":"2003","journal-title":"Gene"},{"key":"10.1016\/j.exphem.2022.09.003_bib0006","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.09.003_bib0007","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.09.003_bib0008","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1038\/s41467-018-05085-9","article-title":"Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis","volume":"9","author":"Asada","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2022.09.003_bib0009","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1038\/ncomms8307","article-title":"Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex","volume":"6","author":"Balasubramani","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2022.09.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109576","article-title":"A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells","volume":"36","author":"Yamamoto","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2022.09.003_bib0011","doi-asserted-by":"crossref","first-page":"e4750","DOI":"10.1371\/journal.pone.0004750","article-title":"Functional conservation of Asxl2, a murine homolog for the Drosophila enhancer of trithorax and polycomb group gene Asx","volume":"4","author":"Baskind","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2022.09.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002038","article-title":"Mouse genome-wide association and systems genetics identify Asxl2 as a regulator of bone mineral density and osteoclastogenesis","volume":"7","author":"Farber","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.exphem.2022.09.003_bib0013","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.celrep.2015.05.019","article-title":"ASXL2 regulates glucose, lipid, and skeletal homeostasis","volume":"11","author":"Izawa","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2022.09.003_bib0014","doi-asserted-by":"crossref","first-page":"15456","DOI":"10.1038\/ncomms15456","article-title":"Loss of Asxl2 leads to myeloid malignancies in mice","volume":"8","author":"Li","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2022.09.003_bib0015","doi-asserted-by":"crossref","first-page":"15429","DOI":"10.1038\/ncomms15429","article-title":"ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia","volume":"8","author":"Micol","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2022.09.003_bib0016","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/10428194.2015.1037754","article-title":"Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21)","volume":"57","author":"Duployez","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2022.09.003_bib0017","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","article-title":"Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking","volume":"34","author":"Dawoud","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.003_bib0018","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/bloodadvances.2020004062","article-title":"Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged \u226580 years","volume":"5","author":"van Zeventer","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2022.09.003_bib0019","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.09.003_bib0020","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2022.09.003_bib0021","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.09.003_bib0022","first-page":"1606","article-title":"Clonal hematopoiesis and nonhematologic disorders","volume":"136","author":"Jaiswal","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.003_bib0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.09.003_bib0024","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1111\/cas.15094","article-title":"Clonal hematopoiesis and associated diseases: a review of recent findings","volume":"112","author":"Asada","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2022.09.003_bib0025","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1038\/bcj.2013.74","article-title":"Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome","volume":"4","author":"Chen","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2022.09.003_bib0026","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.003_bib0027","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2022.09.003_bib0028","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.003_bib0029","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/leu.2010.144","article-title":"The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration","volume":"24","author":"Abdel-Wahab","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204218","article-title":"Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era","volume":"13","author":"Montes-Moreno","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2022.09.003_bib0031","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41375-018-0193-y","article-title":"Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS","volume":"32","author":"Alberti","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.003_bib0032","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1182\/blood-2011-08-368225","article-title":"ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category","volume":"118","author":"Metzeler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.003_bib0033","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.2010.33.4938","article-title":"Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes","volume":"29","author":"Thol","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2022.09.003_bib0034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.24581","article-title":"DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2022.09.003_bib0035","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41467-022-29142-6","article-title":"Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia","volume":"13","author":"Binder","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2022.09.003_bib0036","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20131141","article-title":"Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo","volume":"210","author":"Abdel-Wahab","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2022.09.003_bib0037","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41375-018-0198-6","article-title":"Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification","volume":"33","author":"Uni","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.003_bib0038","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/(SICI)1096-8628(19990827)85:5<438::AID-AJMG2>3.0.CO;2-A","article-title":"Severe end of Opitz trigonocephaly (C) syndrome or new syndrome?","volume":"85","author":"Bohring","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.exphem.2022.09.003_bib0039","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ajmg.a.38686","article-title":"Bohring-Opitz syndrome caused by an ASXL1 mutation inherited from a germline mosaic mother","volume":"176","author":"Bedoukian","year":"2018","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.exphem.2022.09.003_bib0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40364-018-0121-3","article-title":"Acute myeloid leukemia in a father and son with a germline mutation of ASXL1","volume":"6","author":"Seiter","year":"2018","journal-title":"Biomark Res"},{"key":"10.1016\/j.exphem.2022.09.003_bib0041","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-017-0508-x","article-title":"The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model","volume":"10","author":"Hsu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2022.09.003_bib0042","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1084\/jem.20171151","article-title":"Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation","volume":"215","author":"Nagase","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2022.09.003_bib0043","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2017-06-789669","article-title":"Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies","volume":"131","author":"Yang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.003_bib0044","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41375-018-0083-3","article-title":"A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies","volume":"32","author":"Inoue","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.003_bib0045","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.003_bib0046","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.exphem.2015.11.011","article-title":"Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels","volume":"44","author":"Inoue","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2022.09.003_bib0047","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.09.003_bib0048","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2012.262","article-title":"ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome","volume":"27","author":"Schnittger","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.003_bib0049","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/leu.2014.301","article-title":"SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS","volume":"29","author":"Inoue","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.003_bib0050","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2022.09.003_bib0051","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.003_bib0052","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2022.09.003_bib0053","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2011.051532","article-title":"Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value","volume":"97","author":"Pratcorona","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2022.09.003_bib0054","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1158\/2159-8290.CD-19-0152","article-title":"Loss of EZH2 reprograms BCAA metabolism to drive leukemic transformation","volume":"9","author":"Gu","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2022.09.003_bib0055","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1172\/JCI121366","article-title":"Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy","volume":"128","author":"Zhang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2022.09.003_bib0058","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.exphem.2022.09.003_bib0059","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","article-title":"ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22006993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22006993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:37:37Z","timestamp":1759567057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X22006993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":57,"alternative-id":["S0301472X22006993"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2022.09.003","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of ASXL1 in hematopoiesis and myeloid diseases","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2022.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}